首页> 外文期刊>Medecine Nucleaire >Effets secondaires d'un stress par Régadénoson en scintigraphie myocardique chez les patients traités par Ticagrélor
【24h】

Effets secondaires d'un stress par Régadénoson en scintigraphie myocardique chez les patients traités par Ticagrélor

机译:Regadénoson在TicagreloLoR中患者心肌闪烁中Regadénoson的副作用

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction. - As an anti-aggregant that has demonstrated its superiority in the management of acute coronary syndrome, Ticagrelor is an inhibitor of adenosine recapture by red blood cells. Regadenoson, an adenosine agonist, is a preferred cardiac pharmacological stress in patients with a history of spastic bronchopathy. A synergistic effect of both drugs is therefore theoretically expected if they are combined during myocardial scintigraphy. In 2015, European Association of Nuclear Medicine did not rule on the use of Regadenoson in patients previously treated with Ticagrelor. The objective of this work is to study the frequency of adverse events in these patients during Regadenoson stress.Materials and methods. - We retrospectively included patients who underwent a myocardial scintigraphy with pharmacological stress by Regadenoson between February 2016 and February 2019. We compared the frequency of expected side effects of Regadenoson in patients treated with Ticagrelor and not treated with Ticagrelor. The data were analysed using a logistic regression model including patient characteristics and side effects.Results. - Seventeen treated patients were included for 49 untreated patients. There was no significant difference in the frequency of each adverse event between treated and untreated patients. However, a higher number of side effects have been reported in treated patients than in untreated patients. No major adverse event was reported.Conclusion. - In order to rule about the use of Regadenoson in patients treated with Ticagrelor, a larger study is needed to support the hypothesis of more noted minor side effects and which of them should be more encountered. (C) 2019 Elsevier Masson SAS. All rights reserved.
机译:介绍。 - 作为抗统治,证明其在急性冠状动脉综合征的管理方面的优越性,Ticagrelor是红细胞腺苷恢复的抑制剂。腺苷激动剂的Regadenoson是痉挛性支气管病病史的患者中优选的心脏药理应激。因此,理论上,两种药物的协同效应是在心肌闪烁扫描过程中组合的。 2015年,欧洲核医学协会并未对先前用TiCagreloLor治疗的患者使用Regadenoson。这项工作的目的是在Regadenoson rucation中研究这些患者的不良事件的频率。材料和方法。 - 我们回顾性地包括在2016年2月和2019年2月之间通过Regadenoson接受心肌闪烁的患者,从2019年2月之间进行药理压力。我们比较了Regadenoson的预期副作用频率在用TiCagreloR治疗的患者中进行了预期的副作用,而不是用TicagreloR治疗。使用逻辑回归模型分析数据,包括患者特征和副作用。结果。 - 49名未经治疗的患者包含十七名治疗患者。治疗和未经治疗患者之间的每个不良事件的频率没有显着差异。然而,在治疗的患者中报告了较多的副作用而不是未经处理的患者。没有报告主要的不良事件。结论。 - 为了统治用TiCagreloLor治疗的患者使用Regadenoson,需要更大的研究来支持更令人不小的副作用的假设,并且应该更遇到它们中的哪一个。 (c)2019年Elsevier Masson SAS。版权所有。

著录项

  • 来源
    《Medecine Nucleaire》 |2020年第1期|33-39|共7页
  • 作者单位

    Hop Univ Strasbourg Nouvel Hop Civil Serv Biophys & Med Nucl 1 Pl Hop F-67091 Strasbourg France;

    Hop Univ Strasbourg Nouvel Hop Civil Serv Biophys & Med Nucl 1 Pl Hop F-67091 Strasbourg France;

    Hop Univ Strasbourg Nouvel Hop Civil Serv Biophys & Med Nucl 1 Pl Hop F-67091 Strasbourg France;

    Hop Univ Strasbourg Nouvel Hop Civil Serv Biophys & Med Nucl 1 Pl Hop F-67091 Strasbourg France;

    Hop Univ Strasbourg Serv Sante Publ F-67091 Strasbourg France;

    Hop Univ Strasbourg Nouvel Hop Civil Serv Biophys & Med Nucl 1 Pl Hop F-67091 Strasbourg France|Hop Univ Strasbourg Serv Sante Publ F-67091 Strasbourg France|Univ Strasbourg CNRS UMR 7357 Lab ICube F-67000 Strasbourg France;

    Hop Univ Strasbourg Nouvel Hop Civil Serv Biophys & Med Nucl 1 Pl Hop F-67091 Strasbourg France|Univ Strasbourg CNRS UMR 7357 Lab ICube F-67000 Strasbourg France|FMTS Fac Med F-67000 Strasbourg France;

    Hop Univ Strasbourg Nouvel Hop Civil Serv Biophys & Med Nucl 1 Pl Hop F-67091 Strasbourg France|Univ Strasbourg CNRS UMR 7357 Lab ICube F-67000 Strasbourg France|FMTS Fac Med F-67000 Strasbourg France;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 fre
  • 中图分类
  • 关键词

    Myocardial scintigraphy; Regadenoson; Ticagrelor; Adenosine;

    机译:心肌闪烁图;Regadenoson;ticagrelor;腺苷;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号